Excelsior Medical Co., Ltd. AI Stock Analysis
Excelsior Medical Co., Ltd. (4104) AI Stock Analysis
Excelsior Medical Co., Ltd.
(TWSE:4104)
The overall score is constrained by poor cash flow generation and weak technical momentum. The company's strong balance sheet and attractive dividend yield provide support, but the volatile and negative free cash flow is a critical risk that undermines earnings quality. The stock is underperforming technically, which further dampens the near-term outlook.
Excelsior Medical Co., Ltd. (4104) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 13.47B
- Dividend Yield
- 6.04%
- Average Volume (3M)
- 157.48K
- Price to Earnings (P/E)
- 14.6
- Beta (1Y)
- 0.04
- Revenue Growth
- 11.09%
- EPS Growth
- 7.11%
- Country
- TW
- Employees
- 774
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Distribution
Excelsior Medical Co., Ltd. Business Overview & Revenue Model
Company Description
Excelsior Medical Co., Ltd. operates as a distributor of a diverse range of healthcare technology and products throughout various Asian nations, specifically Taiwan, mainland China, Japan, South Korea, Malaysia, and the Philippines. Its extensive por...
Excelsior Medical Co., Ltd. Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is strong with low leverage and improving ROE, but cash flow is deeply negative and volatile, undermining earnings quality. The income statement shows stable but decelerating growth with contracting margins. The overall financial health is bifurcated, with cash flow being a significant red flag.
Income Statement
62PositiveBalance Sheet
75PositiveCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.21B | 8.79B | 8.54B | 8.23B | 7.19B | 6.57B |
| Gross Profit | 1.96B | 1.87B | 1.78B | 1.67B | 1.51B | 1.37B |
| EBITDA | 1.15B | 1.04B | 1.18B | 968.56M | 1.20B | 1.09B |
| Net Income | 894.47M | 805.86M | 771.26M | 746.61M | 667.45M | 607.15M |
Balance Sheet | ||||||
| Total Assets | 21.16B | 18.98B | 20.37B | 18.08B | 16.48B | 15.11B |
| Cash, Cash Equivalents and Short-Term Investments | 4.43B | 3.46B | 4.95B | 3.41B | 3.23B | 3.77B |
| Total Debt | 2.41B | 2.16B | 1.43B | 1.44B | 808.45M | 762.39M |
| Total Liabilities | 7.95B | 7.25B | 9.01B | 7.17B | 6.19B | 5.36B |
| Stockholders Equity | 9.81B | 9.19B | 8.97B | 8.61B | 8.20B | 7.74B |
Cash Flow | ||||||
| Free Cash Flow | 420.88M | -1.27B | 2.35B | -35.54M | 464.62M | 776.29M |
| Operating Cash Flow | 520.04M | -1.19B | 2.47B | 107.10M | 637.13M | 945.05M |
| Investing Cash Flow | 774.62M | -117.73M | -65.57M | -158.46M | -690.00M | 144.13M |
| Financing Cash Flow | -277.20M | 20.30M | -955.96M | -104.51M | -633.89M | -593.91M |
Excelsior Medical Co., Ltd. Peers Comparison
Overall Rating
TW:671273Outperform
TW:473668Neutral
TW:411461Neutral
TW:410454Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | TWD 14.32B | 29.81 | ― | 2.23% | 13.26% | -15.91% | |
| 68Neutral | TWD 13.00B | 6.03 | ― | 4.04% | -0.47% | 45.76% | |
| 61Neutral | TWD 14.35B | 17.11 | ― | 3.18% | 20.99% | 5.70% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | TWD 13.41B | 14.59 | ― | 6.04% | 11.09% | 7.11% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4104 | Excelsior Medical Co., Ltd. | 71.20 | -4.29 | -5.68% | |
| TW:4114 | Synmosa Biopharma Corp | 26.70 | -1.77 | -6.22% | |
| TW:4736 | Taidoc Technology Corporation | 125.50 | 20.09 | 19.06% | |
| TW:6712 | Ever Supreme Bio Technology Co., Ltd. | 142.50 | -10.34 | -6.77% | |
| TW:6748 | ACRO Biomedical Co., Ltd. | 176.00 | 116.43 | 195.47% | |
| TW:7780 | Daiken Biomedical Co., Ltd. | 14.70 | -1.61 | -9.84% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
